123 related articles for article (PubMed ID: 30592785)
1. Central nervous system involvement in primary bone marrow or splenic marginal zone lymphoma: Report of two cases and review of the literature.
Angelopoulou MK; Vassilakopoulos TP; Konstantinou E; Boutsikas G; Asimakopoulos JV; Triantafyllou EF; Petevi K; Kanellopoulos A; Moschogiannis M; Pangalis GA; Siakantaris MP; Konstantopoulos K
Hematol Oncol; 2019 Apr; 37(2):219-222. PubMed ID: 30592785
[No Abstract] [Full Text] [Related]
2. Rare presentation of secondary cutaneous involvement by splenic marginal zone lymphoma: report of a case and review of the literature.
Cohen JM; Nazarian RM; Ferry JA; Takvorian RW; Carter JB
Am J Dermatopathol; 2015 Jan; 37(1):e1-4. PubMed ID: 25238446
[TBL] [Abstract][Full Text] [Related]
3. Splenic marginal zone lymphoma with a de novo t(8;14)(q24;q32) and a prolymphocytoid evolution responsive to rituximab-bendamustine.
Scapinello G; Pizzi M; Vio S; Nabergoj M; Visentin A; Martines A; Bonaldi L; Trentin L; Semenzato G; Piazza F
Ann Hematol; 2018 Oct; 97(10):2001-2003. PubMed ID: 29728736
[No Abstract] [Full Text] [Related]
4. Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma.
Sun X; Liu J; Wang Y; Bai X; Chen Y; Qian J; Zhu H; Liu F; Qiu X; Sun S; Ji N; Liu Y
Oncotarget; 2017 Jul; 8(30):49156-49164. PubMed ID: 28467782
[TBL] [Abstract][Full Text] [Related]
5. First-line treatment with bendamustine and rituximab, in patients with intermediate-/high-risk splenic marginal zone lymphomas.
Castelli R; Bergamaschini L; Deliliers GL
Med Oncol; 2017 Dec; 35(2):15. PubMed ID: 29288421
[TBL] [Abstract][Full Text] [Related]
6. Epidermotropic CXCR3 positive marginal zone lymphoma: a distinctive clinical histopathological entity potentially originating in the skin; it does not always indicate splenic marginal zone lymphoma.
Magro CM; Momtahen S; Coleman M; Grossman ME
Dermatol Online J; 2019 Jul; 25(7):. PubMed ID: 31450275
[TBL] [Abstract][Full Text] [Related]
7. Idelalisib and Rituximab in 17p Deletion-Positive Splenic Marginal Zone Lymphoma.
Philip AZ
J Natl Compr Canc Netw; 2018 Mar; 16(3):230-233. PubMed ID: 29523661
[TBL] [Abstract][Full Text] [Related]
8. Splenic marginal zone lymphoma with increased prolymphocytes.
Cai J; Qing X
Blood; 2021 Jun; 137(22):3150. PubMed ID: 34081119
[No Abstract] [Full Text] [Related]
9. Membranous glomerulonephritis associated with splenic marginal zone lymphoma mimicking multiple myeloma.
Silva GE; Costa RS; Chahud F; Neto OM; Moyses-Neto M; Romão EA; Dantas M
Clin Nephrol; 2013 Jun; 79(6):488-93. PubMed ID: 23725648
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis of splenic B-cell lymphomas in the bone marrow: a review of histopathologic, immunophenotypic, and genetic findings.
Behdad A; Bailey NG
Arch Pathol Lab Med; 2014 Oct; 138(10):1295-301. PubMed ID: 25268192
[TBL] [Abstract][Full Text] [Related]
11. Severe Protein-Losing Enteropathy Due to an Indolent Splenic Lymphoma: Case Report and Review of the Literature.
Naymagon L; Ward S; Naymagon S; Navada S
Clin Lymphoma Myeloma Leuk; 2019 Apr; 19(4):e165-e168. PubMed ID: 30685184
[No Abstract] [Full Text] [Related]
12. Primary central nervous system diffuse large B cell lymphoma transformed from orbital mucosa-associated lymphoid tissue lymphoma: complete response to combined intrathecal and systemic rituximab.
Huang HC; Cheng AL; Lin CW; Kuo SH
Ann Hematol; 2013 Jul; 92(7):989-92. PubMed ID: 23242476
[No Abstract] [Full Text] [Related]
13. Role of blood and bone marrow examination in the diagnosis of mature lymphoid neoplasms in patients presenting with isolated splenomegaly.
Sreedharanunni S; Sachdeva MU; Malhotra P; Ahluwalia J; Naseem S; Prakash G; Khadwal A; Sharma P; Kumar N; Varma N; Varma S; Das R
Hematology; 2015 Oct; 20(9):530-7. PubMed ID: 25760312
[TBL] [Abstract][Full Text] [Related]
14. Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab.
Bennett M; Schechter GP
Semin Hematol; 2010 Apr; 47(2):143-7. PubMed ID: 20350661
[TBL] [Abstract][Full Text] [Related]
15. Splenic marginal zone lymphoma in a patient with chronic hepatitis B.
Christou L; Kalambokis G; Bai M; Kamina S; Tsianos EV
J Gastrointestin Liver Dis; 2009 Dec; 18(4):511-2. PubMed ID: 20076834
[No Abstract] [Full Text] [Related]
16. How to treat splenic marginal zone lymphoma (SMZL) in patients unfit for surgery or more aggressive therapies: experience in 30 cases.
Cervetti G; Ghio F; Cecconi N; Morganti R; Galimberti S; Petrini M
J Chemother; 2017 Apr; 29(2):126-129. PubMed ID: 27454143
[TBL] [Abstract][Full Text] [Related]
17. Treatment of newly diagnosed B-cell origin primary CNS lymphoma with systemic R-IDARAM chemotherapy and intrathecal immunochemotherapy.
Qian L; Zhou C; Shen J; Cen J; Yin W
Oncotarget; 2016 May; 7(18):25783-90. PubMed ID: 27029056
[TBL] [Abstract][Full Text] [Related]
18. Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphoma.
Olszewski AJ; Ali S
Ann Hematol; 2014 Mar; 93(3):449-58. PubMed ID: 24057925
[TBL] [Abstract][Full Text] [Related]
19. Splenic B-cell lymphomas with more than 55% prolymphocytes in blood: evidence for prolymphocytoid transformation.
Hoehn D; Miranda RN; Kanagal-Shamanna R; Lin P; Medeiros LJ
Hum Pathol; 2012 Nov; 43(11):1828-38. PubMed ID: 22520947
[TBL] [Abstract][Full Text] [Related]
20. Post-transplant hepatosplenic T-cell lymphoma successfully treated with HyperCVAD regimen.
Tey SK; Marlton PV; Hawley CM; Norris D; Gill DS
Am J Hematol; 2008 Apr; 83(4):330-3. PubMed ID: 17876769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
